The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.
WNT signaling plays a key role in the self-renewal of tumor initiation cells (TICs). In this study, we used pyrvinium pamoate (PP), an FDA-approved antihelmintic drug that inhibits WNT signaling, to test whether pharmacologic inhibition of WNT signaling can specifically target TICs of aggressive bre...
Main Authors: | Wei Xu, Lara Lacerda, Bisrat G Debeb, Rachel L Atkinson, Travis N Solley, Li Li, Darren Orton, John S McMurray, Brian I Hang, Ethan Lee, Ann H Klopp, Naoto T Ueno, James M Reuben, Savitri Krishnamurthy, Wendy A Woodward |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3754994?pdf=render |
Similar Items
-
Pyrvinium Pamoate and Structural Analogs Are Early Macrofilaricide Leads
by: Emma L. Gunderson, et al.
Published: (2022-02-01) -
Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug
by: Christopher W. Schultz, et al.
Published: (2022-12-01) -
Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer
by: Yitian Li
Published: (2021-05-01) -
Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo
by: Yali Li, et al.
Published: (2022-12-01) -
A CLINICAL STUDY OF THE USE OF PYRVINIUM PAMOATE WITH PIPERAZINE (VANPAR®) IN THE TREATMENT OF OXYURIASIS AND ASCARIASIS
by: M.A. Barzgar, et al.
Published: (1974-03-01)